{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ORPHAN DRUG|Designated/Approved|Treatment of Duchenne Muscular Dystrophy." in comments (approximate match)
Showing 1 - 5 of 5 results
Status:
US Approved Rx
(2021)
Source:
NDA213026
(2021)
Source URL:
First approved in 2021
Source:
NDA213026
Source URL:
Class:
NUCLEIC ACID
Status:
US Approved Rx
(2020)
Source:
NDA212154
(2020)
Source URL:
First approved in 2020
Source:
NDA212154
Source URL:
Class:
NUCLEIC ACID
Status:
US Approved Rx
(2019)
Source:
NDA211970
(2019)
Source URL:
First approved in 2019
Source:
NDA211970
Source URL:
Class:
NUCLEIC ACID
Status:
US Approved Rx
(2016)
Source:
NDA206488
(2016)
Source URL:
First approved in 2016
Source:
NDA206488
Source URL:
Class:
NUCLEIC ACID
Status:
US Approved Rx
(2024)
Source:
ANDA216720
(2024)
Source URL:
First approved in 2017
Source:
NDA208685
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Deflazacort is a glucocorticoid developed for the treatment of different inflammatory and immune conditions. The drug is rapidly metabolized to an active metabolite, 21-hydroxy-deflazaxort that may cross the blood brain barrier. Deflazacort acts by suppressing inflammatory response.
